Attached files
file | filename |
---|---|
8-K - FORM 8-K - Enertopia Corp. | form8k.htm |
Press Release #201604 | FOR IMMEDIATE RELEASE | February 9, 2016 |
Enertopia Announces V-LoveTM Patent Update
Vancouver, BCEnertopia Corporation (ENRT-OTCBB) (TOP-CSE) (the "Company" or "Enertopia") announces further to its original provisional patent filing in October 2015 it has applied for PCT ( Patent Cooperation Treaty) patent protection of V-LoveTM with respect to claims involving lubrication, pH balance and the bioavailability of certain vitamins and minerals via absorption through the vaginal mucosal membrane.
Enertopia has filed a PCT patent application with the United States Patent and Trademark Office regarding its technology.
Enertopias patent-pending formulations were developed in part with the goal of achieving much higher levels of lubrication, thus reducing the potential for vaginal micro tears. However, patent-pending these compositions also provide greater bioavailability of ingredients such as water based vitamins via absorption through the vaginal mucosal membrane than would otherwise be absorbed by the daily oral intake of water based vitamins.
It is in the Companys best interests to have filed the PCT patent application to protect the Companys formulations as evidence has shown that vaginal suppositories have had greater bioavailability results than the common oral intake of water soluble vitamins. The greater the opportunity for water soluble based vitamins to replenish the body, the better the overall health as water based vitamins need to be replenished on a daily basis.
V-LoveTM is specifically balanced for a womans healthy vaginal pH balance of 3.8 to 4.5. While this is on the acidic side of the pH scale, it is nowhere near the acidity of the average stomach acid that has a pH of 1.5. This allows for slower decay of vitamins and minerals compared to oral intake, which in turn allows for greater absorption potential over time. In addition, absorption through the vaginal mucosal membrane avoids the first-pass metabolism that occurs with oral administration of water soluble vitamins (metabolism that occurs in the intestine and portal circulation of the liver before reaching systemic circulation).
V-LoveTM patent-pending formulation meets the needs of providing increased vaginal lubrication to decrease the chance of vaginal micro tears and providing water based vitamins with increased bioavailability, all under the protection of a healthy vaginal pH balance.
These are exciting times for Enertopia. We are very proud about our PCT patent application being filed and all the hard work and dedication by our team. We look forward to providing updates and further developments about our Company. Stated Robert McAllister, President of Enertopia.
About Enertopia
The Companys mission is to empower people with a better way of living through healthy lifestyle choices in helping you live your life your way. Our core values of honesty, integrity, and commitment help to define our corporate practices and demonstrate our dedication in helping individuals whether they are encountering health issues based on age, diet or have suffered a traumatic physical, mental or an emotional event.
Enertopias shares are quoted in Canada with symbol TOP and in the United States with symbol ENRT. For additional information, please visit www.enertopia.com or v-love.co or call Robert McAllister: (250) 765-6412
FORWARD-LOOKING STATEMENTS
This release includes
forward-looking statements. Statements which are not historical facts are
forward-looking statements. The Company makes forward-looking public statements
concerning its expected future financial position, results of operations, cash
flows, financing plans, business strategy, products and services, competitive
positions, growth opportunities, plans and objectives of management for future
operations, including statements that include words such as anticipate, if,
believe, plan, estimate, expect, intend, may, could, should,
will, and other similar expressions are forward-looking statements. Such
forward-looking statements are estimates reflecting the Companys best judgment
based upon current information and involve a number of risks and uncertainties,
and there can be no assurance that other factors will not affect the accuracy of
such forward-looking statements. Access to capital, or lack thereof, is a major
risk and there is no assurance that the Company will be able to raise required
working capital. Factors which could cause actual results to differ materially
from those estimated by the Company include, but are not limited to, government
regulation, managing and maintaining growth, the effect of adverse publicity,
litigation, competition and other factors which may be identified from time to
time in the Companys public announcements and filings. There is no assurance
that existing capital is sufficient for the Companys needs or that it will need
to attempt to raise additional capital. There is no assurance that any planned
corporate activity, business venture, or initiative will be pursued, or if
pursued, will be successful. There is no assurance that any water based product
will promote, assist, or maintain any beneficial human health conditions
whatsoever. There is no assurance that the infusion of vitamins in the water
based personal lubricant will provide any increase in bioavailability to any
individual person. There is no assurance that provisional patent-pending
applications will result in granted patents, or that competing companies, in
their normal course of business, might not introduce other unrelated inventions
superior to the Companys own. No statement herein has been evaluated by the
Food and Drug Administration (FDA). V-LoveTM products are not
intended to diagnose, treat, cure or prevent any disease.
The CSE has not reviewed and does not accept responsibility for the adequacy or accuracy of this release